Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient
Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient have?
Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient has 16 citations in the OpenAlex counts ScholarIQ stores.
When was Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient published?
Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient has 2020 year in the ScholarIQ index.
What is the open-access status of Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient?
Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient has gold oa status in the ScholarIQ index.
What is the DOI of Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient?
The DOI for Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient is on the source record.
What is the PMID of Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient?
The PMID for Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient is on the source record.
What is the OpenAlex record for Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient?
The OpenAlex for Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient is on the source record.